These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 25987014)

  • 1. Tumor infiltrating lymphocytes in ovarian cancer.
    Gasparri ML; Attar R; Palaia I; Perniola G; Marchetti C; Di Donato V; Farooqi AA; Papadia A; Panici PB
    Asian Pac J Cancer Prev; 2015; 16(9):3635-8. PubMed ID: 25987014
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor infiltrating lymphocytes in ovarian cancer.
    Santoiemma PP; Powell DJ
    Cancer Biol Ther; 2015; 16(6):807-20. PubMed ID: 25894333
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ovarian Cancer Immunotherapy: Turning up the Heat.
    Ghisoni E; Imbimbo M; Zimmermann S; Valabrega G
    Int J Mol Sci; 2019 Jun; 20(12):. PubMed ID: 31208030
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment Regimen, Surgical Outcome, and T-cell Differentiation Influence Prognostic Benefit of Tumor-Infiltrating Lymphocytes in High-Grade Serous Ovarian Cancer.
    Wouters MC; Komdeur FL; Workel HH; Klip HG; Plat A; Kooi NM; Wisman GB; Mourits MJ; Arts HJ; Oonk MH; Yigit R; de Jong S; Melief CJ; Hollema H; Duiker EW; Daemen T; de Bruyn M; Nijman HW
    Clin Cancer Res; 2016 Feb; 22(3):714-24. PubMed ID: 26384738
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ovarian cancer creates a suppressive microenvironment to escape immune elimination.
    Yigit R; Massuger LF; Figdor CG; Torensma R
    Gynecol Oncol; 2010 May; 117(2):366-72. PubMed ID: 20144842
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patient inflammatory status and CD4+/CD8+ intraepithelial tumor lymphocyte infiltration are predictors of outcomes in high-grade serous ovarian cancer.
    Pinto MP; Balmaceda C; Bravo ML; Kato S; Villarroel A; Owen GI; Roa JC; Cuello MA; Ibañez C
    Gynecol Oncol; 2018 Oct; 151(1):10-17. PubMed ID: 30078505
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Are tumor-infiltrating lymphocytes protagonists or background actors in patient selection for cancer immunotherapy?
    Zito Marino F; Ascierto PA; Rossi G; Staibano S; Montella M; Russo D; Alfano R; Morabito A; Botti G; Franco R
    Expert Opin Biol Ther; 2017 Jun; 17(6):735-746. PubMed ID: 28318336
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor-infiltrating T cells in epithelial ovarian cancer: predictors of prognosis and biological basis of immunotherapy.
    Wang W; Zou W; Liu JR
    Gynecol Oncol; 2018 Oct; 151(1):1-3. PubMed ID: 30243508
    [No Abstract]   [Full Text] [Related]  

  • 9. Tumor-infiltrating lymphocytes expressing the tissue resident memory marker CD103 are associated with increased survival in high-grade serous ovarian cancer.
    Webb JR; Milne K; Watson P; Deleeuw RJ; Nelson BH
    Clin Cancer Res; 2014 Jan; 20(2):434-44. PubMed ID: 24190978
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Clinical study on immunotherapy of ovarian cancer with tumor infiltrating lymphocytes].
    Hua Z; Lu J; Li H
    Zhonghua Fu Chan Ke Za Zhi; 1996 Sep; 31(9):555-7. PubMed ID: 9275430
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic impact of programmed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor-infiltrating lymphocytes in ovarian high grade serous carcinoma.
    Darb-Esfahani S; Kunze CA; Kulbe H; Sehouli J; Wienert S; Lindner J; Budczies J; Bockmayr M; Dietel M; Denkert C; Braicu I; Jöhrens K
    Oncotarget; 2016 Jan; 7(2):1486-99. PubMed ID: 26625204
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adoptive immunotherapy against ovarian cancer.
    Mittica G; Capellero S; Genta S; Cagnazzo C; Aglietta M; Sangiolo D; Valabrega G
    J Ovarian Res; 2016 May; 9(1):30. PubMed ID: 27188274
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neoadjuvant Chemotherapy of Ovarian Cancer Results in Three Patterns of Tumor-Infiltrating Lymphocyte Response with Distinct Implications for Immunotherapy.
    Lo CS; Sanii S; Kroeger DR; Milne K; Talhouk A; Chiu DS; Rahimi K; Shaw PA; Clarke BA; Nelson BH
    Clin Cancer Res; 2017 Feb; 23(4):925-934. PubMed ID: 27601594
    [No Abstract]   [Full Text] [Related]  

  • 14. PD-L1 expression is associated with tumor-infiltrating T cells and favorable prognosis in high-grade serous ovarian cancer.
    Webb JR; Milne K; Kroeger DR; Nelson BH
    Gynecol Oncol; 2016 May; 141(2):293-302. PubMed ID: 26972336
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of tumor-infiltrating lymphocytes in patients with solid tumors: Can a drop dig a stone?
    Badalamenti G; Fanale D; Incorvaia L; Barraco N; Listì A; Maragliano R; Vincenzi B; Calò V; Iovanna JL; Bazan V; Russo A
    Cell Immunol; 2019 Sep; 343():103753. PubMed ID: 29395859
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ex vivo expanded tumour-infiltrating lymphocytes from ovarian cancer patients release anti-tumour cytokines in response to autologous primary ovarian cancer cells.
    Owens GL; Price MJ; Cheadle EJ; Hawkins RE; Gilham DE; Edmondson RJ
    Cancer Immunol Immunother; 2018 Oct; 67(10):1519-1531. PubMed ID: 30039427
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CD103+ intraepithelial T cells in high-grade serous ovarian cancer are phenotypically diverse TCRαβ+ CD8αβ+ T cells that can be targeted for cancer immunotherapy.
    Komdeur FL; Wouters MC; Workel HH; Tijans AM; Terwindt AL; Brunekreeft KL; Plat A; Klip HG; Eggink FA; Leffers N; Helfrich W; Samplonius DF; Bremer E; Wisman GB; Daemen T; Duiker EW; Hollema H; Nijman HW; de Bruyn M
    Oncotarget; 2016 Nov; 7(46):75130-75144. PubMed ID: 27650547
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic value of tumor PD-L1 expression combined with CD8
    Wang Q; Lou W; Di W; Wu X
    Int Immunopharmacol; 2017 Nov; 52():7-14. PubMed ID: 28846888
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical significance of the immune microenvironment in ovarian cancer patients.
    Yang L; Wang S; Zhang Q; Pan Y; Lv Y; Chen X; Zuo Y; Hao D
    Mol Omics; 2018 Oct; 14(5):341-351. PubMed ID: 30129640
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer.
    Strickland KC; Howitt BE; Shukla SA; Rodig S; Ritterhouse LL; Liu JF; Garber JE; Chowdhury D; Wu CJ; D'Andrea AD; Matulonis UA; Konstantinopoulos PA
    Oncotarget; 2016 Mar; 7(12):13587-98. PubMed ID: 26871470
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.